Relapsing-remitting multiple sclerosis and Skin atrophy

Summary:

Skin atrophy is found among people with Relapsing-remitting multiple sclerosis, especially for people who are female, 40-49 old.

The study analyzes which people have Skin atrophy with Relapsing-remitting multiple sclerosis. It is created by eHealthMe based on reports of 29 people who have Relapsing-remitting multiple sclerosis from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.

What is Relapsing-remitting multiple sclerosis?

Relapsing-remitting multiple sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged) is found to be associated with 126 drugs and 178 conditions by eHealthMe. Check the latest studies of Relapsing-remitting multiple sclerosis.

What is Skin atrophy?

Skin atrophy (wasting of skin) is found to be associated with 624 drugs and 716 conditions by eHealthMe. Check the latest studies of Skin atrophy.

On Jul, 31, 2026

29 people who have Relapsing-Remitting Multiple Sclerosis and Skin Atrophy are studied.

Would you have Skin atrophy when you have Relapsing-remitting multiple sclerosis?

Gender of people who have Relapsing-Remitting Multiple Sclerosis and experienced Skin Atrophy *:

female: 82.76 %
male: 17.24 %

Age of people who have Relapsing-Remitting Multiple Sclerosis and experienced Skin Atrophy *:

Common co-existing conditions for these people *:

Hypersensitivity: 7 people, 24.14%
Chronic Thyroiditis (long lasting inflammation of thyroid gland): 7 people, 24.14%
Birth Control: 7 people, 24.14%
Headache (pain in head): 2 people, 6.90%
Depression: 2 people, 6.90%
Tremor (trembling or shaking movements in one or more parts of your body): 1 person, 3.45%
Stress And Anxiety: 1 person, 3.45%
Sleep Disorder: 1 person, 3.45%
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 1 person, 3.45%
Pain: 1 person, 3.45%

Common drugs taken by these people *:

Ocrevus: 24 people, 82.76%
Cetirizine Hydrochloride: 5 people, 17.24%
Acetaminophen: 5 people, 17.24%
Folic Acid: 5 people, 17.24%
Levothyroxine Sodium: 5 people, 17.24%
Escitalopram: 4 people, 13.79%
Gabapentin: 3 people, 10.34%
Ibuprofen: 3 people, 10.34%
Magnesium: 3 people, 10.34%
Dalfampridine: 3 people, 10.34%

Common symptoms for these people *:

Gait Disturbance: 21 people, 72.41%
Fatigue (feeling of tiredness): 19 people, 65.52%
Headache (pain in head): 17 people, 58.62%
Weakness: 17 people, 58.62%
Rashes (redness): 11 people, 37.93%
Limb Discomfort (discomfort in leg): 11 people, 37.93%
Malaise (a feeling of general discomfort or uneasiness): 10 people, 34.48%
Nasopharyngitis (inflammation of the nasopharynx): 9 people, 31.03%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 9 people, 31.03%
Appendicitis Noninfective (inflammation of the appendix-noninfective): 8 people, 27.59%

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Skin atrophy?

- Check whether Skin atrophy is associated with a drug or a condition

Related studies:

Treatments, associated drugs and conditions:

Relapsing-remitting multiple sclerosis (76,275 reports)
Skin atrophy (6,670 reports)

All the drugs that are associated with Skin atrophy:

Skin atrophy (624 drugs)

All the conditions that are associated with Skin atrophy:

Skin atrophy (716 conditions)

How the study uses the data?

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

The study is based on Skin atrophy and Relapsing-remitting multiple sclerosis, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.